EvolveImmune Therapeutics Provides Corporate and Program Update Highlighted by Closing of $37 Million Financing
December 13, 2023 07:00 ET
|
EvolveImmune
Fundraising Includes Strategic Investment by Bristol Myers Squibb Coupled with Support from Existing Investors EvolveImmune Initiates Chemistry, Manufacturing, and Control (CMC) Activities for Lead...
MRTX Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Mirati Therapeutics, Inc. to Bristol Myers Squibb
October 20, 2023 09:01 ET
|
Wohl & Fruchter LLP
MONSEY, N.Y., Oct. 20, 2023 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Mirati Therapeutics, Inc. (Nasdaq: MRTX) (“Mirati”) to...
Autolus Therapeutics Announces Collaboration with Bristol Myers Squibb for Use of Autolus’ Proprietary Safety Switch System
October 04, 2022 07:00 ET
|
Autolus Therapeutics plc
- Bristol Myers Squibb to receive access to Autolus’ RQR8 safety switch for use in cell therapy programs - - Autolus to receive an upfront payment, with potential for near term option...
TURNING POINT THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of TPTX and Encourages Investors to Contact the Firm
June 06, 2022 14:19 ET
|
Bragar Eagel & Squire
NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors...
Simio Sync 2022: Practical Applications Comes to a Successful Conclusion
March 10, 2022 14:00 ET
|
Simio LLC
PITTSBURGH, March 10, 2022 (GLOBE NEWSWIRE) -- Simio is delighted to announce the successful conclusion of its fifth Simio Sync event titled "Practical Applications". The virtual conference...
Triphase Accelerator Announces Positive Interim Results of Phase 1 Trial of TRPH-222 in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
December 07, 2020 16:30 ET
|
Triphase Accelerator
TORONTO and SAN DIEGO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Triphase Accelerator, a private drug development company dedicated to advancing novel compounds through clinical proof-of-concept, today...
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of MyoKardia, Inc. Buyout
October 05, 2020 21:00 ET
|
Rigrodsky & Long, P.A.
WILMINGTON, Del., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating MyoKardia, Inc. (“MyoKardia”) (NASDAQ GS: MYOK) regarding possible breaches of...
MYOKARDIA ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of MYOK and Encourages Investors to Contact the Firm
October 05, 2020 14:57 ET
|
Bragar Eagel & Squire
NEW YORK, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of...
Global Antidepressant Market: Increased Stress Levels over the Covid-19 Outbreak - PMI
June 30, 2020 10:40 ET
|
PMI
Covina, CA, June 30, 2020 (GLOBE NEWSWIRE) -- The global antidepressant market accounted for US$ 13.2 billion in 2019 and is estimated to be US$ 26.1 billion by 2029 and is anticipated to register a...
Jounce Therapeutics Regains Worldwide Rights to JTX-8064 from Bristol Myers Squibb
June 04, 2020 08:00 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., June 04, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...